# A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

Source: https://onco.cc/trials/nct06971614/  
OnCo record `nct06971614` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of T3011 in bladder & urothelial cancer, run by ImmVira Pharma Co. Ltd, now recruiting.

## Summary

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC is a phase 2 interventional study registered as NCT06971614 by ImmVira Pharma Co. Ltd, with 160 participants planned, started 2025-06-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: T3011.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06971614
- Phase: 2
- Setting: An Open-Label, International, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Intravesical T3011 Injection in Participants With BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) or BCG-Exposed, Chemotherapy-Unresponsive Intermediate /High-Risk NMIBC
- Sponsor: ImmVira Pharma Co. Ltd
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT06971614: https://clinicaltrials.gov/study/NCT06971614

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [T3011](https://onco.cc/drugs/t3011/)
- companies: [ImmVira Pharma](https://onco.cc/companies/immvira-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06971614.json